Table of Contents
ST. LOUIS — Ther-Rx Corp. and Perrigo Co. have released Gynazole-1 vaginal cream to pharmacies for prescribing.
A subsidiary of K-V Pharmaceutical Co., Ther-Rx said Thursday that Gynazole-1 (butoconazole nitrate vaginal cream 2%) is now available at national and regional retail pharmacy chains nationwide. The medication is indicated for the local treatment of yeast infections in nonpregnant women.
Ther-Rx has partnered with Perrigoto manufacture Gynazole-1.
"We are pleased to be able to once again offer Gynazole-1 to prescribing health care providers and to patients in need of therapy," commented Greg Divis, president of Ther-Rx and chief executive officer of K-V Pharmaceutical. "The availability of Gynazole-1 represents a positive step forward for the company as we continue to provide quality, patient-friendly products to support the health of women across the stages of their lives."
The company described Gynazole-1 at the only one-dose, anytime prescription cream for the treatment of vaginal yeast infections caused by all Candida species in nonpregnant women.
"Women experiencing vaginal infections are eager for treatments that provide fast initial relief from symptoms and convenience in dosing and administration," stated David Gandell, M.D., clinical professor of obstetrics and gynecology at the University of Rochester School of Medicine and Dentistry. "Gynazole-1 is a well-established treatment option, so it’s great to be able to prescribe it for my patients again."
